Xisomab 3G3 for Blood Clot Prevention in Cancer Patients

Palo Alto (17 mi)

Overseen byJoseph Shatzel, M.D.

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: OHSU Knight Cancer Institute

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial studies how well Xisomab 3G3 prevents blood clots in cancer patients with catheters receiving chemotherapy. The drug helps stop clot-forming proteins, reducing the risk of clots. This is important because these patients often develop painful and risky blood clots.

Eligibility Criteria

This trial is for adults with solid cancers like lymphoma or multiple myeloma who need a central venous catheter for chemotherapy. They must be in fairly good health, not on blood thinners, and have no major bleeding risks or recent thrombosis. Women of childbearing age must test negative for pregnancy and agree to use contraception.

Treatment Details

The study tests Xisomab 3G3's effectiveness at preventing blood clots in patients with cancer receiving chemo through a catheter. It's a phase II trial where the drug, an antibody designed to stop clots from forming around the catheter site, will be given before starting standard cancer therapy.

1Treatment groups

Experimental Treatment

Group I: Supportive Care (xisomab 3G3)Experimental Treatment1 Intervention

Patients receive xisomab 3G3 IV or via catheter within 48 hours of catheter placement. Patients then receive standard of care chemotherapy 2 days later. After approximately 2 weeks, patients undergo standard of care ultrasound for possible CAT.